ReviewCurrent osteoporosis reports2013
Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
Review in Current osteoporosis reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 96 citations in OpenAlex.
- Trial
- Trial
- Weight loss lifestyle intervention and bone health hormonal markers in type 2 diabetes: analysis from look AHEAD study.Journal of the Endocrine Society · 2026Article
- Pathophysiology and Molecular Signalling in Osteoporosis: Linking Risk Factors to Bone Loss.Journal of cellular and molecular medicine · 2026Review
- Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment.International journal of molecular sciences · 2026Review
- Targeting cancer-induced skeletal damage: a holistic approach to understanding pathophysiology, mechanisms, and management solutions.American journal of cancer research · 2025Review
- Optimization and Implication of Adipose-Derived Stem Cells in Craniofacial Bone Regeneration and Repair.Bioengineering (Basel, Switzerland) · 2024Review
- Exploring the Role of Hormones and Cytokines in Osteoporosis Development.Biomedicines · 2024Review
- Skeletal phenotypes and molecular mechanisms in aging mice.Zoological research · 2024Review
- Prevalence of osteoporosis and associated factors among people aged 50 years and older in the Madhesh province of Nepal: a community-based cross-sectional study.Journal of health, population, and nutrition · 2024Article
- Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.Current rheumatology reports · 2024Review
- Biologics: Teriparatide and Newer Anabolics.Indian journal of orthopaedics · 2023Review
- The Inflammatory Contribution of B-Lymphocytes and Neutrophils in Progression to Osteoporosis.Cells · 2023Review
- Managing Early Onset Osteoporosis: The Impact of Premature Ovarian Insufficiency on Bone Health.Journal of clinical medicine · 2023Review
- Schnurri-3 inhibition suppresses bone and joint damage in models of rheumatoid arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34) in Osteoporosis.Pharmaceutics · 2023Article
- WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- AAV-mediated delivery of osteoblast/osteoclast-regulating miRNAs for osteoporosis therapy.Molecular therapy. Nucleic acids · 2022Article
- Article
- Osteoporosis pathogenesis and treatment: existing and emerging avenues.Cellular & molecular biology letters · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Osteoporotic fractures result in significant morbidity and mortality. Anabolic agents reverse the negative skeletal balance that characterizes osteoporosis by stimulating osteoblast-dependent bone formation to a greater degree than osteoclast-dependent bone resorption. Parathyroid hormone (PTH) and parathyroid hormone- related protein (PTHrP) are peptide hormones, which have anabolic actions when administered intermittently. The only FDA-approved anabolic bone agent for the treatment of osteoporosis in the United States is PTH 1-34, or teriparatide, administered by daily subcutaneous injections. However, PTH 1-84 is also available in Europe. Synthetic human PTHrP 1-36 and a PTHrP 1-34 analog, BA058, have also been shown to increase lumbar spine bone density. These agents and several other PTH and PTHrP analogs, including some which are not administered as injections, continue to be investigated as potential anabolic therapies for osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.